<DOC>
	<DOCNO>NCT01058538</DOCNO>
	<brief_summary>This Phase I/II study patient solid tumor renal cell carcinoma ( RCC ; Phase II part ) . L19-IL2 tumor target immunocytokine constitute single chain Fragment variable ( scFv ) format direct ED-B domain fibronectin , one important marker neoangiogenesis , human cytokine interleukin-2 ( IL2 ) .</brief_summary>
	<brief_title>A Dose Finding Pharmacokinetic Study Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein Patients With Advanced Solid Tumours</brief_title>
	<detailed_description>This open-label , non-randomised , multicentre , Phase I/II study ass safety , pharmacokinetics ( PK ) , early sign activity L19-IL2 monotherapy . In first part study , 5 dose escalation step sequential cohort patient advance solid tumour . In second part study , patient advance RCC give fix dose L19IL2 RD .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>For first part study : histologically cytologically confirm solid cancer evidence advance disease standard treatment available appropriate . For second part study : Histologically cytologically confirm advanced RCC . Patients must least one measurable lesion detect computed tomography ( CT ) . All acute toxic effect ( exclude alopecia ) prior therapy must resolve National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) ( v3.0 ) Grade &lt; /=1 . Patients receive autologous marrow/stem cell infusion use monoclonal antibodypurged specimen eligible . Adult patient sex age 18 year old . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /=2 . Sufficient haematological , liver renal function : Absolute neutrophil count ( ANC ) &gt; /=1.5 x 109/L , platelet &gt; /=100 x 109/L , haemoglobin ( Hb ) &gt; /=9.0 g/dL , Alkaline phosphatase ( AP ) &lt; /=3 x upper limit reference range ( ULN ) alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &lt; /=3 x ULN , bilirubin &lt; 1.5 x ULN ; however , presence liver metastasis , AP &lt; /=5 x ULN ALT and/or AST &lt; /=5 x ULN , bilirubin &lt; 1.5 x ULN , Creatinine &lt; /=ULN , 24 h creatinine clearance &gt; /=50 mL/min . Pulse oximetry &gt; 94 % room air . Negative serum pregnancy test female childbearing potential within 14 day start treatment . Life expectancy least 3 month . Evidence personally sign date informed consent indicate patient ( legally acceptable representative ) inform pertinent aspect study . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . Negative human immunodeficiency virus ( HIV ) test 2 3 week administration study treatment ( informed consent test take ) . Presence active infection ( eg require antibiotic therapy ) severe concurrent disease , , opinion investigator , would place patient undue risk interfere study . Presence known brain metastasis . Chronic aggressive hepatitis active autoimmune disease . History within last year acute subacute coronary syndrome include myocardial infarction , unstable severe stable angina pectoris . Heart insufficiency ( &gt; Grade II New York Heart Association [ NYHA ] criterion ) . Irreversible cardiac arrhythmia require permanent medication . Uncontrolled hypertension . Ischaemic peripheral vascular disease ( Grade IIbIV ) . Severe rheumatoid arthritis . Severe diabetic retinopathy . Recovery major trauma include surgery within 4 week administration study treatment . Known history allergy intravenously administer proteins/peptides/antibodies . Pregnancy breast feed . Female patient must agree use effective contraception , surgically sterile postmenopausal . The definition effective contraception base judgement principal investigator designate associate . Chemotherapy ( standard experimental ) within 4 week administration study treatment , 6 week nitrous urea , lphenylalanine mustard ( LPAM ) temozolamide . Radiation therapy within 4 week administration study treatment . Previous vivo exposure monoclonal antibody biological therapy 6 week administration study treatment . Growth factor immunomodulatory agent within 7 day administration study treatment . Prior allograft ( include bone marrow stem cell ) . Patient require take corticosteroid immunosuppressant drug long term basis . Limited use corticosteroid treat prevent acute hypersensitivity reaction consider exclusion criterion . Investigational study drug take within 4 week administration study treatment concurrent treatment anticancer therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Interleukin , IL2 , monoclonal , antibody , cytokine , tumour targeting , solid tumour , dose finding , renal cell carcinoma , fusion protein , RCC ,</keyword>
	<keyword>L19</keyword>
</DOC>